Table 4.
PCL-2 | PCL-6 | PCL-6 | |||||
---|---|---|---|---|---|---|---|
6 months (n = 156) | |||||||
Not clinically significant | Clinically significant | Not clinically significant | Clinically significant (>15) | Not clinically significant | Clinically significant (>12) | ||
PCL | Not clinically significant | 113 (72%) | 0 | 113 (72%) | 0 | 113 (73%) | 0 |
Clinically significant (>20) | 26 (17%) | 18 (11%) | 39 (25%) | 4 (3%) | 27 (17%) | 16 (10%) |
12 months (n = 138) | |||||||
---|---|---|---|---|---|---|---|
Not clinically significant | Clinically significant | Not clinically significant | Clinically significant (≥15) | Not clinically significant | Clinically significant (≥12) | ||
PCL | Not clinically significant | 68 (49%) | 20 (14%) | 88 (64%) | 0 (0%) | 87 (63%) | 1 (1%) |
Clinically significant (≥20) | 1 (1%) | 50 (36%) | 39 (28%) | 11 (8%) | 25 (18%) | 25 (18%) |